321 related articles for article (PubMed ID: 35720417)
1. TIGIT as a Promising Therapeutic Target in Autoimmune Diseases.
Yue C; Gao S; Li S; Xing Z; Qian H; Hu Y; Wang W; Hua C
Front Immunol; 2022; 13():911919. PubMed ID: 35720417
[TBL] [Abstract][Full Text] [Related]
2. TIGIT: An emerging immune checkpoint target for immunotherapy in autoimmune disease and cancer.
Zhao J; Li L; Yin H; Feng X; Lu Q
Int Immunopharmacol; 2023 Jul; 120():110358. PubMed ID: 37262959
[TBL] [Abstract][Full Text] [Related]
3. Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity.
Dixon KO; Schorer M; Nevin J; Etminan Y; Amoozgar Z; Kondo T; Kurtulus S; Kassam N; Sobel RA; Fukumura D; Jain RK; Anderson AC; Kuchroo VK; Joller N
J Immunol; 2018 Apr; 200(8):3000-3007. PubMed ID: 29500245
[TBL] [Abstract][Full Text] [Related]
4. T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain as a promising immune checkpoint target for the treatment of SLE.
Zhao J; Li L; Feng X; Fan X; Yin H; Lu Q
Lupus; 2024 Mar; 33(3):209-216. PubMed ID: 38291414
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory receptor agonists: the future of autoimmune disease therapeutics?
Grebinoski S; Vignali DA
Curr Opin Immunol; 2020 Dec; 67():1-9. PubMed ID: 32619929
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint receptors in autoimmunity.
Burke KP; Patterson DG; Liang D; Sharpe AH
Curr Opin Immunol; 2023 Feb; 80():102283. PubMed ID: 36709596
[TBL] [Abstract][Full Text] [Related]
7. The relationship between TIGIT
Lee DJ
Int Immunopharmacol; 2020 Jun; 83():106378. PubMed ID: 32172208
[TBL] [Abstract][Full Text] [Related]
8. The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity.
Schnell A; Bod L; Madi A; Kuchroo VK
Cell Res; 2020 Apr; 30(4):285-299. PubMed ID: 31974523
[TBL] [Abstract][Full Text] [Related]
9. Tim-3, Lag-3, and TIGIT.
Joller N; Kuchroo VK
Curr Top Microbiol Immunol; 2017; 410():127-156. PubMed ID: 28900677
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoints in central nervous system autoimmunity.
Joller N; Peters A; Anderson AC; Kuchroo VK
Immunol Rev; 2012 Jul; 248(1):122-39. PubMed ID: 22725958
[TBL] [Abstract][Full Text] [Related]
11. DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.
Shibuya A; Shibuya K
Int Immunol; 2021 Nov; 33(12):687-692. PubMed ID: 34694361
[TBL] [Abstract][Full Text] [Related]
12. TIGIT as an emerging immune checkpoint.
Harjunpää H; Guillerey C
Clin Exp Immunol; 2020 May; 200(2):108-119. PubMed ID: 31828774
[TBL] [Abstract][Full Text] [Related]
13. TIGIT in cancer immunotherapy.
Chauvin JM; Zarour HM
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900861
[TBL] [Abstract][Full Text] [Related]
14. TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy.
Liu XG; Hou M; Liu Y
Immunol Invest; 2017 Feb; 46(2):172-182. PubMed ID: 27819527
[TBL] [Abstract][Full Text] [Related]
15. The TIGIT/CD226 axis regulates human T cell function.
Lozano E; Dominguez-Villar M; Kuchroo V; Hafler DA
J Immunol; 2012 Apr; 188(8):3869-75. PubMed ID: 22427644
[TBL] [Abstract][Full Text] [Related]
16. Expansion of circulating peripheral TIGIT+CD226+ CD4 T cells with enhanced effector functions in dermatomyositis.
Li W; Deng C; Yang H; Lu X; Li S; Liu X; Chen F; Chen L; Shu X; Zhang L; Liu Q; Wang G; Peng Q
Arthritis Res Ther; 2021 Jan; 23(1):15. PubMed ID: 33413573
[TBL] [Abstract][Full Text] [Related]
17. HTLV-1 bZIP Factor Impairs Anti-viral Immunity by Inducing Co-inhibitory Molecule, T Cell Immunoglobulin and ITIM Domain (TIGIT).
Yasuma K; Yasunaga J; Takemoto K; Sugata K; Mitobe Y; Takenouchi N; Nakagawa M; Suzuki Y; Matsuoka M
PLoS Pathog; 2016 Jan; 12(1):e1005372. PubMed ID: 26735971
[TBL] [Abstract][Full Text] [Related]
18. TIGIT immune checkpoint blockade restores CD8
Guillerey C; Harjunpää H; Carrié N; Kassem S; Teo T; Miles K; Krumeich S; Weulersse M; Cuisinier M; Stannard K; Yu Y; Minnie SA; Hill GR; Dougall WC; Avet-Loiseau H; Teng MWL; Nakamura K; Martinet L; Smyth MJ
Blood; 2018 Oct; 132(16):1689-1694. PubMed ID: 29986909
[TBL] [Abstract][Full Text] [Related]
19. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
[TBL] [Abstract][Full Text] [Related]
20. Agonistic anti-TIGIT treatment inhibits T cell responses in LDLr deficient mice without affecting atherosclerotic lesion development.
Foks AC; Ran IA; Frodermann V; Bot I; van Santbrink PJ; Kuiper J; van Puijvelde GH
PLoS One; 2013; 8(12):e83134. PubMed ID: 24376654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
